The path to approval for uniQure’s gene therapy candidate for Huntington’s disease is in doubt as the US Food and Drug ...

An experimental gene therapy slowed Huntington’s by up to 75 percent in a small clinical trial. While not a cure, it may give patients longer lives.

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the ...

In a groundbreaking first, a gene therapy in clinical trials has slowed the progression of Huntington's disease, a rare genetic disorder in which toxic bits of protein cause brain cells to malfunction ...

These movements tend to worsen when the person feels anxious or distracted, and as the disease advances, they become more frequent and harder to manage. According to the National Institute of ...

Pivotal results from uniQure’s gene therapy for Huntington’s disease have brought new light to patients who have known only ...

UniQure stock crashed Monday on "confusing" and "unexpected" feedback from the FDA for its Huntington's disease gene therapy.

Researchers announce breakthrough results for AMT-130, the first disease-modifying treatment for Huntington's disease, with ...

A woman whose mother, aunt and grandmother died from Huntington's disease has described a breakthrough in treating the ...

LEXINGTON, Mass. and AMSTERDAM, Nov. 03, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing ...

MRI of a brain with Huntington's Disease. Every week neurologist Victor Sung sees people with Huntington’s disease, a rare and devastating neurodegenerative disorder, at his clinic at the University ...

(CNN) - There may be some hope for those living with Huntington’s disease after a new experimental gene therapy was reportedly found to slow the progression of the disease. Drugmaker Uniqure announced ...